Cargando…

Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis

Nontuberculous mycobacterial (NTM) pulmonary infections in people with cystic fibrosis (CF) are associated with significant morbidity and mortality and are increasing in prevalence. Host risk factors for NTM infection in CF are largely unknown. We hypothesize that the airway microbiota represents a...

Descripción completa

Detalles Bibliográficos
Autores principales: Breen, Paul, Zimbric, Madsen, Opron, Kristopher, Caverly, Lindsay J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241540/
https://www.ncbi.nlm.nih.gov/pubmed/35477313
http://dx.doi.org/10.1128/msphere.00104-22
_version_ 1784737829163630592
author Breen, Paul
Zimbric, Madsen
Opron, Kristopher
Caverly, Lindsay J.
author_facet Breen, Paul
Zimbric, Madsen
Opron, Kristopher
Caverly, Lindsay J.
author_sort Breen, Paul
collection PubMed
description Nontuberculous mycobacterial (NTM) pulmonary infections in people with cystic fibrosis (CF) are associated with significant morbidity and mortality and are increasing in prevalence. Host risk factors for NTM infection in CF are largely unknown. We hypothesize that the airway microbiota represents a host risk factor for NTM infection. In this study, 69 sputum samples were collected from 59 people with CF; 42 samples from 32 subjects with NTM infection (14 samples collected before incident NTM infection and 28 samples collected following incident NTM infection) were compared to 27 samples from 27 subjects without NTM infection. Sputum samples were analyzed with 16S rRNA gene sequencing and metabolomics. A supervised classification and correlation analysis framework (sparse partial least-squares discriminant analysis [sPLS-DA]) was used to identify correlations between the microbial and metabolomic profiles of the NTM cases compared to the NTM-negative controls. Several metabolites significantly differed in the NTM cases compared to controls, including decreased levels of tryptophan-associated and branched-chain amino acid metabolites, while compounds involved in phospholipid metabolism displayed increased levels. When the metabolome and microbiome data were integrated by sPLS-DA, the models and component ordinations showed separation between the NTM and control samples. While this study could not determine if the observed differences in sputum metabolites between the cohorts reflect metabolic changes that occurred as a result of the NTM infection or metabolic features that contributed to NTM acquisition, it is hypothesis generating for future work to investigate host and bacterial community factors that may contribute to NTM infection risk in CF. IMPORTANCE Host risk factors for nontuberculous mycobacterial (NTM) infection in people with cystic fibrosis (CF) are largely unclear. The goal of this study was to help identify potential host and bacterial community risk factors for NTM infection in people with CF, using microbiome and metabolome data from CF sputum samples. The data obtained in this study identified several metabolic profile differences in sputum associated with NTM infection in CF, including 2-methylcitrate/homocitrate and selected ceramides. These findings represent potential risk factors and therapeutic targets for preventing and/or treating NTM infections in people with CF.
format Online
Article
Text
id pubmed-9241540
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-92415402022-06-30 Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis Breen, Paul Zimbric, Madsen Opron, Kristopher Caverly, Lindsay J. mSphere Research Article Nontuberculous mycobacterial (NTM) pulmonary infections in people with cystic fibrosis (CF) are associated with significant morbidity and mortality and are increasing in prevalence. Host risk factors for NTM infection in CF are largely unknown. We hypothesize that the airway microbiota represents a host risk factor for NTM infection. In this study, 69 sputum samples were collected from 59 people with CF; 42 samples from 32 subjects with NTM infection (14 samples collected before incident NTM infection and 28 samples collected following incident NTM infection) were compared to 27 samples from 27 subjects without NTM infection. Sputum samples were analyzed with 16S rRNA gene sequencing and metabolomics. A supervised classification and correlation analysis framework (sparse partial least-squares discriminant analysis [sPLS-DA]) was used to identify correlations between the microbial and metabolomic profiles of the NTM cases compared to the NTM-negative controls. Several metabolites significantly differed in the NTM cases compared to controls, including decreased levels of tryptophan-associated and branched-chain amino acid metabolites, while compounds involved in phospholipid metabolism displayed increased levels. When the metabolome and microbiome data were integrated by sPLS-DA, the models and component ordinations showed separation between the NTM and control samples. While this study could not determine if the observed differences in sputum metabolites between the cohorts reflect metabolic changes that occurred as a result of the NTM infection or metabolic features that contributed to NTM acquisition, it is hypothesis generating for future work to investigate host and bacterial community factors that may contribute to NTM infection risk in CF. IMPORTANCE Host risk factors for nontuberculous mycobacterial (NTM) infection in people with cystic fibrosis (CF) are largely unclear. The goal of this study was to help identify potential host and bacterial community risk factors for NTM infection in people with CF, using microbiome and metabolome data from CF sputum samples. The data obtained in this study identified several metabolic profile differences in sputum associated with NTM infection in CF, including 2-methylcitrate/homocitrate and selected ceramides. These findings represent potential risk factors and therapeutic targets for preventing and/or treating NTM infections in people with CF. American Society for Microbiology 2022-04-28 /pmc/articles/PMC9241540/ /pubmed/35477313 http://dx.doi.org/10.1128/msphere.00104-22 Text en Copyright © 2022 Breen et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Breen, Paul
Zimbric, Madsen
Opron, Kristopher
Caverly, Lindsay J.
Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis
title Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis
title_full Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis
title_fullStr Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis
title_full_unstemmed Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis
title_short Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis
title_sort sputum metabolites associated with nontuberculous mycobacterial infection in cystic fibrosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241540/
https://www.ncbi.nlm.nih.gov/pubmed/35477313
http://dx.doi.org/10.1128/msphere.00104-22
work_keys_str_mv AT breenpaul sputummetabolitesassociatedwithnontuberculousmycobacterialinfectionincysticfibrosis
AT zimbricmadsen sputummetabolitesassociatedwithnontuberculousmycobacterialinfectionincysticfibrosis
AT opronkristopher sputummetabolitesassociatedwithnontuberculousmycobacterialinfectionincysticfibrosis
AT caverlylindsayj sputummetabolitesassociatedwithnontuberculousmycobacterialinfectionincysticfibrosis